Background
To the authors' knowledge, it is unknown whether patientâreported symptom severity and symptom interference with daily activities differ between younger (aged <65 years) and older (aged â„65 years) women receiving similar chemotherapy regimens for early breast cancer (EBC).
Methods
Study participants rated 17 side effects of chemotherapy regimens currently in use in clinical practice (2014â2019).
Results
Of 284 women with EBC (stage IâIII), approximately 57% were aged <65 years and 43% were aged â„65 years. For anthracyclineâbased regimens, a higher percentage of younger women reported moderate, severe, or very severe (MSVS) hot flashes (49% vs 18%) (P < .001). For nonanthracycline regimens, a higher percentage of younger women reported MSVS hot flashes (38% vs 19%) (P = .009) and a lower percentage reported MSVS arthralgia (28% vs 49%) (P = .005). With regard to symptom interference with daily activities, a higher percentage of younger women being treated with anthracyclineâbased regimens reported MSVS hot flashes (32% vs 7%) (P = .001) and myalgia (38% vs 18%) (P = .02). For nonanthracycline chemotherapy, a higher percentage of younger women reported MSVS interference for hot flashes (26% vs 9%) (P = .006) and lower percentages reported abdominal pain (13% vs 28%) (P = .02). Overall, there were no significant differences noted among younger versus older patients with regard to hospitalizations (19% vs 12%; P = .19), dose reductions (34% vs 31%; P = .50), dose delays (22% vs 25%; P = .59), or early treatment discontinuation (16% vs 16%; P = .9546).
Conclusions
Older and younger women with EBC who were treated with identical chemotherapy regimens generally experienced similar levels of symptom severity, symptomârelated interference with daily activities, and adverse events.
Lay Summary
In this study, women receiving chemotherapy for early breast cancer rated the severity of 17 symptoms and symptom interference with their activities of daily living.
Older (aged â„65 years) and younger (aged <65 years) women who received identical chemotherapy regimens generally experienced similar levels of symptom severity, symptomârelated interference with daily activities, and adverse events.